Patents by Inventor Matthew P. Goetz

Matthew P. Goetz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240058318
    Abstract: Methods and material for treating cancer (e.g., estrogen receptor negative (ER?) and estrogen receptor positive (ER+) breast cancer) are described herein. For example, methods and materials for targeting degradation of protein kinase C type beta (PKC?1) polypeptides in mammals with ER? cancers are described.
    Type: Application
    Filed: December 10, 2021
    Publication date: February 22, 2024
    Inventors: Matthew P. Goetz, Thomas R. Caulfield, John Randolph Hawse, IV
  • Patent number: 11865163
    Abstract: This document provides methods and materials for using butyrylcholinesterases (BChE) to treat cancer (e.g., triple negative breast cancer or prostate cancer). For example, methods and materials for using nucleic acid vectors (e.g., viral vectors) to express BChE polypeptides under conditions that reduce the number of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) and/or reduce the growth rate of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) are provided.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: January 9, 2024
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: William S. Brimijoin, Liewei Wang, Yang Gao, Ping Chen, Liyi Geng, Jia Yu, Judy C. Boughey, Matthew P. Goetz
  • Publication number: 20230079757
    Abstract: This document relates to methods and materials involved in assessing and/or treating mammals (e g , humans) having cancer. For example, methods and materials that can be used to determine whether or not the cancer is likely to be responsive to a particular cancer treatment (e.g., a cancer immunotherapy or a cancer chemotherapy) are provided. For example, methods and materials that can be used to treat a mammal by administering one or more cancer treatments that is/are selected based, at least in part, on whether or not the mammal is likely to be responsive to a particular cancer treatment also are provided.
    Type: Application
    Filed: February 18, 2021
    Publication date: March 16, 2023
    Inventors: Haojie Huang, Yundong He, Matthew P. Goetz
  • Patent number: 11497729
    Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using an inhibitor of USP7 polypeptide to increase the sensitivity of cancer cells (e.g., CD340+ cancer cells such as HER2+ cancer cells) to treatment with an inhibitor of a CD340 polypeptide (e.g., an inhibitor of a HER2 polypeptide) are provided. Methods and materials for using USP7 polypeptide inhibitors in combination with CD340 polypeptide inhibitors to treat cancer (e.g., HER2+ breast cancer that was refractory to trastuzumab alone treatment) are provided.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: November 15, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Liewei Wang, Matthew P. Goetz, Judy C. Boughey, Jia Yu, Bo Qin
  • Publication number: 20210283101
    Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using an inhibitor of USP7 polypeptide to increase the sensitivity of cancer cells (e.g., CD340+ cancer cells such as HER2+ cancer cells) to treatment with an inhibitor of a CD340 polypeptide (e.g., an inhibitor of a HER2 polypeptide) are provided. Methods and materials for using USP7 polypeptide inhibitors in combination with CD340 polypeptide inhibitors to treat cancer (e.g., HER2+ breast cancer that was refractory to trastuzumab alone treatment) are provided.
    Type: Application
    Filed: July 7, 2017
    Publication date: September 16, 2021
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Liewei Wang, Matthew P. Goetz, Judy C. Boughey, Jia Yu, Bo Qin
  • Publication number: 20190255154
    Abstract: This document provides methods and materials for using butyrylcholinesterases (BChE) to treat cancer (e.g., triple negative breast cancer or prostate cancer). For example, methods and materials for using nucleic acid vectors (e.g., viral vectors) to express BChE polypeptides under conditions that reduce the number of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) and/or reduce the growth rate of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) are provided.
    Type: Application
    Filed: September 15, 2017
    Publication date: August 22, 2019
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: William S. Brimijoin, Liewei Wang, Yang Gao, Ping Chen, Liyi Geng, Jia Yu, Judy C. Boughey, Matthew P. Goetz
  • Patent number: 10220016
    Abstract: This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: March 5, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Matthew P. Goetz, Judy C. Boughey, Liewei Wang, Krishna R. Kalari, Richard M. Weinshilboum, Vera J. Suman
  • Publication number: 20180021295
    Abstract: This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.
    Type: Application
    Filed: February 17, 2016
    Publication date: January 25, 2018
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Matthew P. Goetz, Judy C. Boughey, Liewei Wang, Krishna R. Kalari, Richard M. Weinshilboum, Vera J. Suman
  • Publication number: 20110136913
    Abstract: This document provides methods and materials related to assessing and treating breast cancer patients. For example, methods and materials that involve assessing a breast cancer patient to determine whether the patient has (1) cancer cells that over express HER-2 polypeptides or comprise a HER-2 amplification and (2) at least an intermediate CYP2D6 metabolizer status are provided.
    Type: Application
    Filed: August 19, 2009
    Publication date: June 9, 2011
    Inventors: Matthew P. Goetz, James N. Ingle, Vera J. Suman, Matthew M. Ames, Carol Reynolds
  • Publication number: 20100248223
    Abstract: This document provides methods and materials related to assessing the likely outcome for mammals (e.g., humans) with cancer (e.g., breast cancer). For example, methods and materials for using the ratio of HOXB13 polypeptide expression to IL-17BR polypeptide expression, CYP2D6 genotype, medication history, or combinations thereof to determine the likelihood of a breast cancer patient to experience breast cancer relapse or death are provided.
    Type: Application
    Filed: May 18, 2007
    Publication date: September 30, 2010
    Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Matthew P. Goetz, James N. Ingle, Fergus J. Couch, Matthew M. Ames
  • Publication number: 20090326333
    Abstract: This document provides methods and materials related to assessing the likely outcome for mammals (e.g., humans) with cancer (e.g., breast cancer). For example, methods and materials for using the ratio of HOXB13 polypeptide expression to IL-17BR polypeptide expression to determine the likelihood of a breast cancer patient to experience breast cancer relapse or death are provided.
    Type: Application
    Filed: December 8, 2006
    Publication date: December 31, 2009
    Inventors: Matthew P. Goetz, Fergus J. Couch, James N. Ingle, Vera J. Suman
  • Publication number: 20090208944
    Abstract: This document provides methods and materials related to assessing the likely outcome for mammals (e.g., humans) with cancer (e.g., breast cancer). For example, methods and materials that involve assessing a breast cancer patient's cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) genotype to determine the likelihood of the beast cancer patient to experience breast cancer relapse or death are provided. Methods and materials that involve assessing the likelihood that a breast cancer patient being treated with tamoxifen will experience side effects such as hot flashes also are provided.
    Type: Application
    Filed: December 8, 2006
    Publication date: August 20, 2009
    Inventors: Matthew P. Goetz, James N. Ingle, Richard M. Weinshilboum, Fergus J. Couch, Matthew M. Ames